Phase 1 Food Effect Study for Alicaforsen Tablets
A Two-Period, Randomised, Crossover Study Designed to Evaluate the In Vivo Performance of a Modified Release Formulation of Alicaforsen in Healthy Male Subjects in the Fed and Fasted State
Sponsor: Atlantic Pharmaceuticals Ltd
A PHASE1 clinical study on IBD, this trial is completed. The trial is conducted by Atlantic Pharmaceuticals Ltd and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Atlantic Pharmaceuticals Ltd
For direct contact, visit the study record on ClinicalTrials.gov .